About
Built for the people
commercializing science.
Vainture is incubated by CelesiumAI and based in Houston, Texas. We replace months of manual commercialization and patentability analysis with AI-driven evaluation — so research institutions and venture firms can make faster, better-evidenced decisions about what to fund and what to file.
Our Story
Incubated by CelesiumAI.
Vainture was created in 2026 to solve a problem the Houston research ecosystem keeps running into: exceptional science failing to reach patients or markets — not because the ideas are bad, but because institutional evaluation bottlenecks make them invisible or mis-prioritized.
The discipline that makes investment committees effective — filter rigorously, de-risk what survives — had never been operationalized for the academic commercialization pipeline. Vainture is that system.
Developed in collaboration with faculty across Houston's leading research institutions, including Baylor College of Medicine, Rice University, MD Anderson Cancer Center, and the Texas Medical Center. Designed for the decision rooms where science meets capital.
How Vainture evaluates
Two engines, co-equal.
Vainture has evolved to evaluate ventures across two complementary engines. Vainture Signal scores commercialization viability across six dimensions. Vainture Patent assesses patentability against seven prior art sources. Each engine produces an independent verdict; the two run in parallel when both questions are open. Built for research institutions where commercialization and patentability are distinct decision gates, often owned by different teams.
01 — Evaluate (commercialization)
Vainture Signal
Scientists submit ideas or paste existing IP. AI returns a structured Commercialization Viability Report scored across market, competitive, regulatory, investor, partner, and funding dimensions.
02 — Evaluate (patentability)
Vainture Patent
The same disclosure runs through a 7-source prior art search and citation-gated relevance scoring. Output: defensibility verdict, 0–100 score, draft claims at three scope levels, and a practitioner-ready DOCX handoff.
03 — Direct
Portfolio Dashboard + Trend Intelligence
Institutional leadership sees the full pipeline scored and ranked. Filter by therapeutic area, development stage, or recommendation. Market signals across therapeutic areas steer research toward areas with the highest combined commercialization-and-patentability probability.
Who it's for
Built for the people commercializing science.
Research Institutions
Baylor College of Medicine, Rice University, MD Anderson, UH, UTHealth
Replace manual evaluation of invention disclosures. Move faster on the ones that matter, decline the ones that don't — with evidence.
Venture Firms
Seed and Series A biotech, medtech, digital health
See investment-ready opportunities surfaced from institutional pipelines. Use the same AI evaluation as part of due diligence.
Operators & Investors
Fund managers, tech-transfer leaders, research VPs
Benchmark your pipeline against therapeutic-area trends. Know which bets are supported by the market — and which aren't.
Talk with us.
Vainture is currently onboarding institutional partners and venture firms. If that's you, we'd like to hear what you're working on.
Request Access